Brazil’s Coronavirus provides a global laboratory for the chaos vaccine race

Brazil, where the number of cases has now crossed 2 million, is one of a handful of sites for testing experimental coronavirus vaccines. It offers an unusual and attractive mix of research: a skyrocketing rate of transmission, as well as an internationally respected research center and a public health system experienced in creating and delivering vaccines.

Both Phase 3 trials will involve Brazil and at least 14,000 Brazilians are scheduled to be involved. According to Brazilian institutions consulted by CNN, advanced negotiations are underway to introduce three more vaccine trials in the country.

However, Brazil’s president, Jair Bolonaro, has repeatedly brought down the virus as a “small flu” and has been criticized by experts for his reluctance to implement nationwide resistance measures, now within Brazil’s borders Outgoing vaccine research may prove to be a global sport. Variable as a northern hemisphere for a possible second wave in winter.

Julio Barbosa, a 42-year-old nursing technician who has already lost five of Coronovirus’s associates, has volunteered to participate in one of the mass vaccination trials conducted by Oxford University and the pharmaceutical company AstraZeneca. Phase 3 trials will involve 50,000 volunteers from all over the world.

After taking the shot, Barbossa says he had low-grade fever and mild muscle pain that disappeared the following morning. In the trial, involving mostly health workers, half of the volunteers are receiving the trial Kovid-19 vaccine and half are receiving a meningitis vaccine, which may provoke similar symptoms.

“This vaccine will have to come out soon so we can be discharged in the hospital. I haven’t stopped working in the last four months,” he told CNN after receiving a shot at a medical warehouse in Sao Paulo for testing .

Chinese biotech company Synovac is starting a trial of Phase 3 in Brazil in association with the Butanan Institute of Brazil in São Paulo. Its Coronavac test vaccine uses inactivated virus cells to stimulate immune responses in patients. The trial will begin next Monday with 9,000 volunteers in five Brazilian states and the capital.

Like the Oxford vaccine, Coronavac will be given to most health professionals. Ricardo Palacios, medical director of research at Buton, says the institute is “in very advanced conversations with two other vaccines under development” and also in talks with dozens of pharmaceutical companies about the Kovid-19 research study.

“All producers in the world will always be looking for a place that has a high transmission, taking into account the effectiveness of the vaccine. But the infection rate is not enough. A country needs institutions that are international scientific, regulatory and ethical protocols Work with. To carry out the tests, “Palacios told CNN.

Brazil is just such a place, said researcher Natalia Pastrnak of the Vaccine Development Laboratory of the Institute of Biomedical Sciences at the University of São Paulo (USP). He points out that Brazil has advanced logistics and manufacturing installations compared to many other countries such as Kovid-19 in Mexico.

“It is necessary to go to a country where the disease is spreading strongly and where institutions and qualified professionals are conducting tests. Brazil offers these two important factors,” she said.

More than 76,000 people have died of coronovirus in Brazil, and the Pan American Health Organization has warned that the number of cases in this nation of 211 million people will not increase until mid-August.

Preliminary results of the trial are expected to be revealed by the end of the year, and should help reduce the time that vaccines will need to be developed in the earlier stages of development.

Brazilians guaranteed access to future vaccines

Interim Health Minister Eduardo Pazuelo said last month that the “number one goal” of Brazil’s health system is the freedom to produce a vaccine. “We can’t be left out,” he said.

Under the agreements to host the trials, Brazil expects effective vaccination to be able to produce both vaccines at home – rather than buying abroad – a significant benefit for both the country and even its neighbors. .

Coronavirus killed Latin America's political class

Butenon, which produced 100 million flu vaccines last year, is preparing to produce a similar dose to Synovac’s Coronavac if that vaccine proves effective.

“Having a pre-established structure is necessary because Brazil will help make other vaccine agreements. Latin America has some (vaccine) manufacturing plants. Brazil needs to export the vaccine to other countries after participating in its public health system Will be required. ” Palacios, Buttan’s medical director, said.

The Biomanginhos complex in Rio de Janeiro, owned by the Oswaldo Cruz Foundation, is preparing to produce 70 million doses of the Oxford vaccine next year, in the hope that ongoing negotiations between the Brazilian government, Oxford and AstraZeneca will be completed by then.

Meanwhile, the results are yet to come from the Brazilian government’s own experiments of mass distribution of hydroxychloroquine. Medical trials have not shown hydroxychloroquine to be effective as a coronovirus treatment. Nevertheless, Brazil’s mayors, doctors and medical insurance companies continue to distribute a “covid kit” – including hydroxychloroquine, the antibiotic azithromycin, the anti-parasitic drug ivermectin, zinc, and vitamin C in the south, center-cities of the country. West and Northeast region of. With the exception of conflicting results on hydroxychloroquine, none of these treatments have been shown to help coronovirus, either alone or in combination.

Last week, following his own diagnosis with Kovid-19, Bolsonaro released a video in which he praised the unsafe drug, swallowing a pill with a smile on camera. “It’s working for another person. I trust hydroxychloroquine. What about you?” The President said.

Workers hunted coronovirus on Thursday at Villa Formosa Cemetery in São Paulo.

More tests and more data in the future

Soon, more Brazilians may soon be recruited as test subjects for other potential coronavirus-related therapies.

The Federal University of São Paulo (UNICEF), responsible for executing the trial of the Oxford vaccine in Brazil beginning June 20, says it will soon announce a joint trial with Italy’s Lazaro Spalzani National Institute Participated in the development of the vaccine against the Ebola virus.

The Italian institute is currently testing the first phase of its vaccine against Kovid-19. According to Unifus’s Dean Soraya Smiley, after the transition phase receded in Italy, it began to see hard-hit Brazil as a second and third stage location.

“We hope to start it in late August. We will see where the transition will be more prominent in the country when it comes to selecting volunteers, as the transition appears slow in Rio de Janeiro and São Paulo,” Smiley said .

For nursing technician Barbosa, developing any successful vaccine in Brazil would feel like a personal victory. “I’m dreaming about this. The first thing I will do is go to a samba and hug my friends. I’ll also lick the dripping beer on the counter,” he said.